Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment

Haematologica

Volumn 91, Issue 2, 2006, Pages 162-168

  Colombat, Marie ^a,d   Fort, Marie Pierre ^b   Chollet, Claudine ^a   Marit, Gerald ^a,b   Roche, Catherine ^c   Preudhomme, Claude ^c   Reiffers, Josy ^a,b   Praloran, Vincent ^a   Mahon, François Xavier ^a,b,d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib mesylate; RQ PCR

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ACCURACY; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

EID: 33644560018     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967;58:1468-71.
2. Nowell P, Hungerford D. A minute chromosome in human granulocytic leukemia. Science 1960:1497.
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-4.
4. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia 1996;10:751-6.
5. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7.
8. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passenni C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
9. Schindler T, Bornmann W, Pellicena P. Miller WT, Clarkson B, Kunyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
10. Lowenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med 2003;349:1399-401.
11. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423-32.
12. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-32.
13. Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999;13:957-64.
14. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
15. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon-α/ara-C. Leukemia 2003;17:2392-400.
16. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003;17:978-9.
17. Van DV, V, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, Van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-34.
18. Paschka P, Merx K, Hochhaus A. Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance. Acta Haematol 2004;112:85-92.
19. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004;103:2284-90.
20. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004;104:1979-88.
21. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.